Clinical Trials Logo

Keratoconjunctivitis Sicca clinical trials

View clinical trials related to Keratoconjunctivitis Sicca.

Filter by:

NCT ID: NCT05161208 Completed - Dry Eye Clinical Trials

OC-01 (Varenicline) Nasal Spray and Dry Eye Signs and Symptoms in Daily Disposable Contact Lens Wearers

Start date: December 3, 2021
Phase: Phase 4
Study type: Interventional

This study is a single center, prospective, randomized, controlled, double-masked, two-arm investigator-initiated study to investigate the efficacy of OC-01 (varenicline) nasal spray on the signs and symptoms of dry eye disease in daily soft contact lens wearers.

NCT ID: NCT05159284 Recruiting - Dry Eye Clinical Trials

Efficacy and Safety of Topical Hydrocortisone on Signs and Symptoms of Dry Eye Associated to Meibomian Gland Dysfunction

Start date: November 9, 2021
Phase: Phase 4
Study type: Interventional

The purpose of this study is assess the efficacy and safety of topical hydrocortisone (Softacort) for treatment of clinical signs and symptoms of dry eye disease when associated with moderate meibomian gland dysfunction.

NCT ID: NCT05148507 Recruiting - Cataract Clinical Trials

Optimization of the Ocular Surface Prior to Cataract Surgery Using PROKERA

Start date: November 4, 2021
Phase: N/A
Study type: Interventional

The purpose of the study is to assess whether PROKERA can sufficiently stabilize the ocular surface prior to cataract surgery and improve post operative outcomes patients with moderate to severe dry disease.

NCT ID: NCT05136924 Not yet recruiting - Dry Eye Disease Clinical Trials

IIT Assessing OC-01Nasal Spray on Symptoms of DED Following CXL

Start date: December 1, 2021
Phase: Phase 2
Study type: Interventional

A Randomized, Controlled, Double-Masked, Two-Arm Investigator-Initiated study to Assess the Efficacy of OC-01 (varenicline) Nasal Spray on signs and symptoms of Dry Eye Disease in subjects following Corneal Collagen Crosslinking (CXL)

NCT ID: NCT05136170 Completed - Dry Eye Syndrome Clinical Trials

Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease

NGF0221
Start date: January 27, 2022
Phase: Phase 3
Study type: Interventional

The study objective is to assess the efficacy and safety of cenegermin (rhNGF) ophthalmic solution at 20 mcg/mL concentration administered three times daily for 4 weeks in patients with severe Sjogren's dry eye disease (DED) who are under chronic treatment with topical Cyclosporine A (CsA).

NCT ID: NCT05133180 Completed - Dry Eye Clinical Trials

Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study)

Start date: January 19, 2022
Phase: Phase 3
Study type: Interventional

Primary objectives - To compare the efficacy of cenegermin vs vehicle in Schirmer I test (without anaesthesia) >10mm/5min at Week 4 by testing the superiority. - To compare the efficacy of cenegermin vs vehicle in Symptom Assessment in Dry Eye questionnaire (SANDE) global score at Week 12 by testing the superiority. Secondary objectives - To compare the efficacy of cenegermin vs vehicle in Schirmer I test at Week 4, 8, 12 and 16 by testing the superiority. - To compare the efficacy of cenegermin vs vehicle in Cornea and conjunctiva vital staining with fluorescein (National Eye Institute [NEI] scales) at Week 4, 8, 12 and 16 by testing the superiority. - To compare the efficacy of cenegermin vs vehicle in Tear Film Break-Up Time (TFBUT) at Week 4, 8, 12 and 16 by testing the superiority. - To compare the efficacy of cenegermin vs vehicle in SANDE scores at Week 8, 12 and 16 by testing the superiority. - To compare the efficacy of cenegermin vs vehicle in worsening in symptom scores (SANDE) and/or NEI score at Week 4 by testing the superiority. - To compare the efficacy of cenegermin vs vehicle in impact of dry eye on everyday life (IDEEL) questionnaire at Week 4, 8, 12 and 16 by testing the superiority.

NCT ID: NCT05131152 Recruiting - Dry Eye Clinical Trials

Microvascular and Inflammatory Responses of 0.05 Cyclosporine Eye Drop (II) in Treatment of Dry Eye

Start date: December 1, 2021
Phase: N/A
Study type: Interventional

To explore the law of changes in ocular surface inflammation when 0.05% cyclosporine eye drops (II) is used to treat dry eye, 50 cases of mild to moderate dry eyes were included. The expectation is finding out whether cyclosporine has a regulatory effect on conjunctival microvascular parameters and other inflammation indicators after cyclosporine eye drops treat dry eye, and analyze the value of conjunctival microvascular indicators in dry eye immunosuppressive therapy.

NCT ID: NCT05121493 Not yet recruiting - Dry Eye Syndromes Clinical Trials

Study of Platelet Rich Plasma Drops to Moderate Clinically Significant Dry Eye

Start date: May 15, 2024
Phase: N/A
Study type: Interventional

This is a single center double-masked study with up to four visits. Subjects who have been diagnosed with dry-eye syndrome at Flaum Eye Institute will be enrolled. The purpose of the study is to determine if using platelet rich plasma drops can improve clinically significant dry eye in patients and determine if there is a difference with using two different uses of the plasma tear drops: platelet rich plasma tears and plasma tears without platelets.

NCT ID: NCT05120401 Recruiting - Dry Eye Clinical Trials

Causal Relationship Between Dry Eye and Accommodative Spasm

Start date: November 5, 2021
Phase:
Study type: Observational

To investigate the causal relationship of Sicca dry eye patients with presbyopic refractive error and accommodative spasm.

NCT ID: NCT05119920 Completed - Dry Eye Disease Clinical Trials

Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease

Start date: January 3, 2022
Phase: Phase 2
Study type: Interventional

This is a Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Signs and Symptoms of Dry Eye Disease.